• Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Trp100Ter; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583; DepMap=ACH-001973).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; DepMap=ACH-001973).
  

PubMed=3127479; DOI=10.1111/1523-1747.ep12461022
McEwan M., Parsons P.G., Moss D.J.
Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells.
J. Invest. Dermatol. 90:515-519(1988)

PubMed=1697409
Chenevix-Trench G., Martin N.G., Ellem K.A.O.
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990)

PubMed=7780963
Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A., Toso R.J., Herlyn M., Bennett D.C.
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.
Cancer Res. 55:2528-2532(1995)

PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D
White C.A., Thomson S.A., Cooper L.T., van Endert P.M., Tampe R., Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.
Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.
Int. J. Cancer 75:590-595(1998)

PubMed=10070891; DOI=10.1038/sj.bjc.6690147; PMCID=PMC2362648
Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Br. J. Cancer 79:921-926(1999)

PubMed=15048078; DOI=10.1038/sj.onc.1207563
Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K.
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Stark M.S., Hayward N.K.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)

PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Johansson P., Pavey S., Hayward N.K.
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007)